IBRX — ImmunityBio, Inc. Stock Price, Chart & AI Report

Negative Apr 17, 2026 • 03:57 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

Rosen Law Firm is reminding investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 of the May 26, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made false and misleading statements about Anktiva's capabilities and ImmunityBio's business operations and prospects.

IBRX securities class action lead plaintiff deadline false statements investor compensation ImmunityBio

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements about product capabilities (Anktiva) and business operations. Investors who purchased shares during the specified period may have suffered damages, indicating significant corporate governance and disclosure issues.

Negative Apr 16, 2026 • 13:00 UTC GlobeNewswire Inc. • Portnoy Law Firm

Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit on behalf of ImmunityBio investors who purchased securities between January 19-March 24, 2026. The lawsuit was triggered by a 12.13% stock price decline on January 23, 2026, following disappointing Phase 2 clinical trial results for the company's glioblastoma immunotherapy treatment, specifically the failure to reach median overall survival endpoints in the QUILT 3.078 trial.

IBRX class action lawsuit ImmunityBio clinical trial failure glioblastoma stock price decline investor losses Phase 2 results

Sentiment note

The company experienced a significant 12.13% stock price decline due to disappointing Phase 2 clinical trial results that failed to meet critical survival endpoints, leading to loss of investor confidence and triggering a class action lawsuit for shareholder losses.

Negative Apr 15, 2026 • 02:11 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio faces a securities fraud class action lawsuit after the FDA issued a warning letter on March 24, 2026, regarding misleading advertisements for its cancer therapy Anktiva. The warning stated the ads misrepresented the drug's ability to cure and prevent cancer. Following the public disclosure, ImmunityBio's stock price fell 21% to $7.42 per share. Investors who purchased shares between January 19, 2026 and March 24, 2026 have until May 26, 2026 to file lead plaintiff applications.

IBRX securities fraud class action lawsuit FDA warning letter misleading advertisement stock decline cancer therapy Anktiva

Sentiment note

The company faces a securities fraud class action lawsuit due to FDA warning regarding misleading cancer therapy advertisements. The stock declined 21% following the disclosure, and executives are charged with failing to disclose material information, indicating serious regulatory and legal violations.

Negative Apr 13, 2026 • 21:51 UTC GlobeNewswire Inc. • Rosen Law Firm

ZSPC Investor News: If You Have Suffered Losses in zSpace Inc. (NASDAQ: ZSPC), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against zSpace Inc. (ZSPC), Hub Group Inc. (HUBG), and ImmunityBio Inc. (IBRX) on behalf of shareholders, alleging materially misleading business information was issued to investors. The firm is preparing class action lawsuits seeking recovery of investor losses through contingency fee arrangements.

ZSPC HUBG IBRX securities fraud class action lawsuit investor losses misleading information shareholder rights

Sentiment note

Company is involved in a securities class action lawsuit with an important deadline approaching, suggesting alleged securities violations.

Negative Apr 12, 2026 • 20:28 UTC GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (IBRX) for allegedly making false and misleading statements about its lead product Anktiva. The FDA issued a Warning Letter on March 24, 2026, stating that company executives made inaccurate claims that the drug could 'cure and even prevent all cancer.' Following the FDA announcement, IBRX stock fell 21.12% to $7.42 per share. Investors who purchased securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status.

IBRX securities fraud class action lawsuit FDA Warning Letter misleading claims cancer vaccine stock price decline lead plaintiff

Sentiment note

Company faces securities fraud allegations for making materially false and misleading statements about its lead product Anktiva's capabilities. FDA issued a Warning Letter citing inaccurate claims about cancer treatment. Stock declined 21.12% following the FDA announcement, indicating significant investor loss and reputational damage.

Negative Apr 10, 2026 • 22:48 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST

Rosen Law Firm is notifying investors in Aquestive Therapeutics, Franklin BSP Realty Trust, and ImmunityBio about ongoing securities class action lawsuits. Investors who purchased securities during specified class periods are encouraged to secure legal counsel before important deadlines. The lawsuits allege false or misleading statements regarding product applications and disclosures.

AQST FBRT FBRTPE IBRX securities class action investor lawsuit lead plaintiff deadline false statements

Sentiment note

Company is subject to securities class action lawsuit first filed by Rosen Law Firm, indicating alleged false or misleading statements to investors during the specified class period.

Negative Apr 10, 2026 • 22:45 UTC GlobeNewswire Inc. • Hagens Berman

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman

ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA sent a warning letter regarding misleading efficacy claims made by executive chairman Dr. Patrick Soon-Shiong about the company's immunotherapy drug Anktiva. The FDA determined that promotional materials falsely suggested Anktiva could treat all cancers, when it is only approved for non-muscle invasive bladder cancer. The disclosure caused IBRX shares to plunge over 21% on March 24, 2026, erasing nearly $2 billion in market value.

IBRX securities class action FDA warning letter misleading claims Anktiva immunotherapy stock price decline investor losses

Sentiment note

The company faces a securities class action lawsuit due to FDA-flagged misleading efficacy claims about its lead product Anktiva. The regulatory warning resulted in a 21% stock price decline and approximately $2 billion in market capitalization loss, indicating serious legal and reputational damage.

Negative Apr 10, 2026 • 22:31 UTC GlobeNewswire Inc. • Rosen Law Firm

FBRT DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Franklin BSP Realty Trust, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRT

Rosen Law Firm has filed securities class action lawsuits against Franklin BSP Realty Trust (FBRT) and other companies, alleging that defendants made false and misleading statements about business prospects and dividend sustainability during the Class Period. Investors with losses exceeding $100,000 are encouraged to join the class action before the April 27, 2026 lead plaintiff deadline.

FBRT FBRTPE AQST IBRX securities class action Franklin BSP Realty Trust false statements dividend

Sentiment note

Company is subject to a securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations.

Negative Apr 10, 2026 • 21:43 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

Rosen Law Firm is reminding investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 of the May 26, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements about the company's business and overstated the capabilities of Anktiva, resulting in investor damages.

IBRX securities class action ImmunityBio lead plaintiff deadline false statements investor compensation Patrick Soon-Shiong

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements and overstatement of product capabilities (Anktiva), which caused investor damages. This indicates serious corporate governance and disclosure issues.

Negative Apr 10, 2026 • 14:51 UTC GlobeNewswire Inc. • The Schall Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its Anktiva drug capabilities, causing investor losses when the truth was revealed.

IBRX securities fraud class action lawsuit ImmunityBio Anktiva drug false statements investor losses Securities Exchange Act

Sentiment note

The company is the subject of a securities fraud lawsuit for making false and misleading statements about its Anktiva drug capabilities, resulting in material investor losses. This represents serious regulatory and legal violations.

Positive Apr 9, 2026 • 18:11 UTC Benzinga • Vandana Singh

Why Is ImmunityBio Stock Rallying Thursday?

ImmunityBio (IBRX) shares surged 7.02% on Thursday following strong Q1 2026 results with net product revenue of $44.2 million, a 168% year-over-year increase. The company reported 750% unit sales growth for Anktiva in 2025 and expanded approvals across five regulatory jurisdictions covering 34 countries. However, the FDA recently issued a warning regarding unsupported promotional claims about Anktiva's cancer-curing capabilities, prompting the company to review its marketing practices.

IBRX ImmunityBio Anktiva Q1 2026 earnings product revenue growth FDA warning promotional claims NMIBC CIS

Sentiment note

Strong Q1 revenue growth of 168% year-over-year, significant 750% unit sales increase for Anktiva in 2025, expanded global regulatory approvals across 34 countries, and solid cash position of $380.9 million support positive momentum. Stock rallied 7.02% on the news. However, sentiment is tempered by recent FDA warning regarding unsupported promotional claims, which introduces regulatory risk and requires corrective actions.

Negative Apr 8, 2026 • 01:50 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio faces a securities fraud class action lawsuit after the FDA issued a warning letter on March 24, 2026, regarding misleading advertisements for its cancer therapy Anktiva. The warning stated the ads misrepresented the drug's ability to cure and prevent cancer. Following the disclosure, ImmunityBio's stock price fell 21% to $7.42 per share. Investors who purchased shares between January 19, 2026 and March 24, 2026 have until May 26, 2026 to file lead plaintiff applications.

IBRX securities fraud class action lawsuit FDA warning letter misleading advertisement stock decline cancer therapy lead plaintiff

Sentiment note

Company faces securities fraud allegations, FDA warning for misleading drug advertisements, 21% stock price decline, and class action lawsuit. The FDA found that promotional communications created a misleading impression about the drug's efficacy in treating cancer.